Replies to post #142773 on Biotech Values

[iwfal]

However one can easily make the point that high specificity of a treatment could be a negative rather than the Holy Grail it as been touted to be. I believe someone has already made this point on board regarding kinase inhibitors. I will venture that HSP90 inhibitors will have that same benefit of lack of specificity as they modulate a large variety of proteins.

FWIW - agree that the effect will have to be seen. But I'd suggest it is more uncertain than that since interfering in many different links of a complex, intertwined control system actually seems at least as likely to go badly somewhere.

PS As SNTA themselves note - the HSP90 system doesn't appear to interfere equally with all kinases.